

# Richard Price

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8138698/publications.pdf>

Version: 2024-02-01

329  
papers

18,741  
citations

13099

68  
h-index

17105

122  
g-index

343  
all docs

343  
docs citations

343  
times ranked

10923  
citing authors

#	ARTICLE	IF	CITATIONS
1	Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. <i>Lancet</i> , The, 2005, 366, 717-725.	13.7	973
2	Mefloquine resistance in <i>Plasmodium falciparum</i> and increased <i>pfmdr1</i> gene copy number. <i>Lancet</i> , The, 2004, 364, 438-447.	13.7	707
3	Vivax Malaria: Neglected and Not Benign. <i>American Journal of Tropical Medicine and Hygiene</i> , 2007, 77, 79-87.	1.4	675
4	Multidrug-Resistant <i>Plasmodium vivax</i> Associated with Severe and Fatal Malaria: A Prospective Study in Papua, Indonesia. <i>PLoS Medicine</i> , 2008, 5, e128.	8.4	510
5	A Long Neglected World Malaria Map: <i>Plasmodium vivax</i> Endemicity in 2010. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1814.	3.0	448
6	Vivax malaria: neglected and not benign. <i>American Journal of Tropical Medicine and Hygiene</i> , 2007, 77, 79-87.	1.4	445
7	A novel multiple-stage antimalarial agent that inhibits protein synthesis. <i>Nature</i> , 2015, 522, 315-320.	27.8	353
8	The pathophysiology of vivax malaria. <i>Trends in Parasitology</i> , 2009, 25, 220-227.	3.3	347
9	New developments in <i>Plasmodium vivax</i> malaria: severe disease and the rise of chloroquine resistance. <i>Current Opinion in Infectious Diseases</i> , 2009, 22, 430-435.	3.1	300
10	Global extent of chloroquine-resistant <i>Plasmodium vivax</i> : a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 982-991.	9.1	300
11	Mapping the global endemicity and clinical burden of <i>Plasmodium vivax</i> , 2000â€“17: a spatial and temporal modelling study. <i>Lancet</i> , The, 2019, 394, 332-343.	13.7	276
12	Impaired nitric oxide bioavailability and L-arginineâ€“reversible endothelial dysfunction in adults with falciparum malaria. <i>Journal of Experimental Medicine</i> , 2007, 204, 2693-2704.	8.5	270
13	â€œAsymptomaticâ€•Malaria: A Chronic and Debilitating Infection That Should Be Treated. <i>PLoS Medicine</i> , 2016, 13, e1001942.	8.4	259
14	Molecular and Pharmacological Determinants of the Therapeutic Response to Artemether-Lumefantrine in Multidrug-Resistant <i>Plasmodium falciparum</i> Malaria. <i>Clinical Infectious Diseases</i> , 2006, 42, 1570-1577.	5.8	258
15	Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. <i>Lancet</i> , The, 2007, 369, 757-765.	13.7	237
16	Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 17097-17102.	7.1	235
17	The Relationship between Age and the Manifestations of and Mortality Associated with Severe Malaria. <i>Clinical Infectious Diseases</i> , 2008, 47, 151-157.	5.8	214
18	Changes in the Treatment Responses to Artesunate-Mefloquine on the Northwestern Border of Thailand during 13 Years of Continuous Deployment. <i>PLoS ONE</i> , 2009, 4, e4551.	2.5	212

#	ARTICLE	IF	CITATIONS
19	A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. <i>Malaria Journal</i> , 2009, 8, 89.	2.3	204
20	Artemisinin combination therapy for vivax malaria. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 405-416.	9.1	204
21	Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine. <i>American Journal of Tropical Medicine and Hygiene</i> . 2014, 91, 833-843.	1.4	204
22	Quinolone-3-Diarylethers: A New Class of Antimalarial Drug. <i>Science Translational Medicine</i> , 2013, 5, 177ra37.	12.4	187
23	Chloroquine Resistant Plasmodium vivax: In Vitro Characterisation and Association with Molecular Polymorphisms. <i>PLoS ONE</i> , 2007, 2, e1089.	2.5	187
24	Plasmodium vivax. <i>Advances in Parasitology</i> , 2012, 80, 151-201.	3.2	178
25	The anaemia of Plasmodium vivax malaria. <i>Malaria Journal</i> , 2012, 11, 135.	2.3	173
26	Lung Injury in Vivax Malaria: Pathophysiological Evidence for Pulmonary Vascular Sequestration and Posttreatment Alveolar Capillary Inflammation. <i>Journal of Infectious Diseases</i> , 2007, 195, 589-596.	4.0	172
27	Genomic analysis of local variation and recent evolution in Plasmodium vivax. <i>Nature Genetics</i> , 2016, 48, 959-964.	21.4	169
28	Primaquine radical cure of Plasmodium vivax: a critical review of the literature. <i>Malaria Journal</i> , 2012, 11, 280.	2.3	155
29	Plasmodium malariae and P. ovale genomes provide insights into malaria parasite evolution. <i>Nature</i> , 2017, 542, 101-104.	27.8	150
30	Vivax Malaria: A Major Cause of Morbidity in Early Infancy. <i>Clinical Infectious Diseases</i> , 2009, 48, 1704-1712.	5.8	147
31	Plasmodium vivax in the Era of the Shrinking P. falciparum Map. <i>Trends in Parasitology</i> , 2020, 36, 560-570.	3.3	135
32	Growing evidence of Plasmodium vivax across malaria-endemic Africa. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007140.	3.0	135
33	In Vivo Parasitological Measures of Artemisinin Susceptibility. <i>Journal of Infectious Diseases</i> , 2010, 201, 570-579.	4.0	133
34	Adverse Pregnancy Outcomes in an Area Where Multidrug-Resistant Plasmodium vivax and Plasmodium falciparum Infections Are Endemic. <i>Clinical Infectious Diseases</i> , 2008, 46, 1374-1381.	5.8	131
35	Dihydroartemisinin-Piperaquine versus Artesunate-Amodiaquine: Superior Efficacy and Posttreatment Prophylaxis against Multidrug-Resistant Plasmodium falciparum and Plasmodium vivax Malaria. <i>Clinical Infectious Diseases</i> , 2007, 44, 1067-1074.	5.8	129
36	Relationship of Cell-Free Hemoglobin to Impaired Endothelial Nitric Oxide Bioavailability and Perfusion in Severe Falciparum Malaria. <i>Journal of Infectious Diseases</i> , 2009, 200, 1522-1529.	4.0	124

#	ARTICLE	IF	CITATIONS
37	Plasmodium vivax Recurrence Following Falciparum and Mixed Species Malaria: Risk Factors and Effect of Antimalarial Kinetics. <i>Clinical Infectious Diseases</i> , 2011, 52, 612-620.	5.8	124
38	KAF156 Is an Antimalarial Clinical Candidate with Potential for Use in Prophylaxis, Treatment, and Prevention of Disease Transmission. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5060-5067.	3.2	122
39	Parasite Biomass-Related Inflammation, Endothelial Activation, Microvascular Dysfunction and Disease Severity in Vivax Malaria. <i>PLoS Pathogens</i> , 2015, 11, e1004558.	4.7	120
40	Determinants of In Vitro Drug Susceptibility Testing of <i>Plasmodium vivax</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1040-1045.	3.2	119
41	Parasite-Dependent Expansion of TNF Receptor II-Positive Regulatory T Cells with Enhanced Suppressive Activity in Adults with Severe Malaria. <i>PLoS Pathogens</i> , 2009, 5, e1000402.	4.7	118
42	A new <i>Plasmodium vivax</i> reference sequence with improved assembly of the subtelomeres reveals an abundance of pir genes. <i>Wellcome Open Research</i> , 2016, 1, 4.	1.8	118
43	Major Burden of Severe Anemia from Non-Falciparum Malaria Species in Southern Papua: A Hospital-Based Surveillance Study. <i>PLoS Medicine</i> , 2013, 10, e1001575.	8.4	117
44	Mefloquine Pharmacokinetic-Pharmacodynamic Models: Implications for Dosing and Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 3414-3424.	3.2	112
45	Pyrazoleamide compounds are potent antimalarials that target Na <sup>+</sup> homeostasis in intraerythrocytic <i>Plasmodium falciparum</i> . <i>Nature Communications</i> , 2014, 5, 5521.	12.8	108
46	High Deformability of <i>Plasmodium vivax</i> -Infected Red Blood Cells under Microfluidic Conditions. <i>Journal of Infectious Diseases</i> , 2009, 199, 445-450.	4.0	107
47	Short-course primaquine for the radical cure of <i>Plasmodium vivax</i> malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. <i>Lancet</i> , The, 2019, 394, 929-938.	13.7	106
48	The Global Public Health Significance of <i>Plasmodium vivax</i> . <i>Advances in Parasitology</i> , 2012, 80, 1-111.	3.2	105
49	Malaria eradication and elimination: views on how to translate a vision into reality. <i>BMC Medicine</i> , 2015, 13, 167.	5.5	101
50	World Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malaria. <i>Malaria Journal</i> , 2007, 6, 121.	2.3	99
51	Artemisinin drugs: novel antimalarial agents. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 1815-1827.	4.1	97
52	An open dataset of <i>Plasmodium falciparum</i> genome variation in 7,000 worldwide samples. <i>Wellcome Open Research</i> , 2021, 6, 42.	1.8	97
53	L-arginine and Vitamin D Adjunctive Therapies in Pulmonary Tuberculosis: A Randomised, Double-Blind, Placebo-Controlled Trial. <i>PLoS ONE</i> , 2013, 8, e70032.	2.5	93
54	A Simple Score to Predict the Outcome of Severe Malaria in Adults. <i>Clinical Infectious Diseases</i> , 2010, 50, 679-685.	5.8	89

#	ARTICLE	IF	CITATIONS
55	Type I Interferons Regulate Immune Responses in Humans with Blood-Stage Plasmodium falciparum Infection. <i>Cell Reports</i> , 2016, 17, 399-412.	6.4	88
56	The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1025-1034.	9.1	85
57	Platelets kill circulating parasites of all major Plasmodium species in human malaria. <i>Blood</i> , 2018, 132, 1332-1344.	1.4	85
58	Identifying and combating the impacts of COVID-19 on malaria. <i>BMC Medicine</i> , 2020, 18, 239.	5.5	84
59	Hidden Biomass of Intact Malaria Parasites in the Human Spleen. <i>New England Journal of Medicine</i> , 2021, 384, 2067-2069.	27.0	82
60	Clinical and Pharmacological Determinants of the Therapeutic Response to Dihydroartemisinin-Piperaquine for Drug-Resistant Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 4090-4097.	3.2	81
61	Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea. <i>PLoS Pathogens</i> , 2020, 16, e1009133.	4.7	81
62	Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia. <i>BMC Medicine</i> , 2014, 12, 217.	5.5	80
63	Estimating the Proportion of Plasmodium vivax Recurrences Caused by Relapse: A Systematic Review and Meta-Analysis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1094-1099.	1.4	77
64	Simplified antimalarial therapeutic monitoring: using the day-7 drug level?. <i>Trends in Parasitology</i> , 2008, 24, 159-163.	3.3	76
65	Lung Injury in Uncomplicated and Severe Falciparum Malaria: A Longitudinal Study in Papua, Indonesia. <i>Journal of Infectious Diseases</i> , 2005, 192, 1966-1974.	4.0	74
66	Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity. <i>Malaria Journal</i> , 2008, 7, 249.	2.3	74
67	The effect of dose on the antimalarial efficacy of artemether+lumefantrine: a systematic review and pooled analysis of individual patient data. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 692-702.	9.1	74
68	Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. <i>PLoS Medicine</i> , 2017, 14, e1002379.	8.4	74
69	Recovery of Endothelial Function in Severe Falciparum Malaria: Relationship with Improvement in Plasma Arginine and Blood Lactate Concentrations. <i>Journal of Infectious Diseases</i> , 2008, 198, 602-608.	4.0	73
70	Dihydroartemisinin-Piperaquine Versus Chloroquine in the Treatment of Plasmodium vivax Malaria in Thailand: A Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2011, 53, 977-984.	5.8	71
71	A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria. <i>ACS Infectious Diseases</i> , 2016, 2, 945-957.	3.8	71
72	Plasmodium malariae Infection Associated with a High Burden of Anemia: A Hospital-Based Surveillance Study. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0004195.	3.0	71

#	ARTICLE	IF	CITATIONS
73	Increased Asymmetric Dimethylarginine in Severe <i>Falciparum</i> Malaria: Association with Impaired Nitric Oxide Bioavailability and Fatal Outcome. <i>PLoS Pathogens</i> , 2010, 6, e1000868.	4.7	70
74	Phenotypic and genotypic characterisation of drug-resistant <i>Plasmodium vivax</i> . <i>Trends in Parasitology</i> , 2012, 28, 522-529.	3.3	70
75	The <i>Plasmodium falciparum</i> transcriptome in severe malaria reveals altered expression of genes involved in important processes including surface antigen-encoding var genes. <i>PLoS Biology</i> , 2018, 16, e2004328.	5.6	67
76	Antibodies to <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> Merozoite Surface Protein 5 in Indonesia: Species-Specific and Cross-Reactive Responses. <i>Journal of Infectious Diseases</i> , 2008, 198, 134-142.	4.0	65
77	Diagnosis and Treatment of <i>Plasmodium vivax</i> Malaria. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 35-51.	1.4	65
78	Comparison of three molecular methods for the detection and speciation of <i>Plasmodium vivax</i> and <i>Plasmodium falciparum</i> . <i>Malaria Journal</i> , 2007, 6, 124.	2.3	64
79	Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of <i>Plasmodium vivax</i> infection in Ethiopia: A randomized controlled trial. <i>PLoS Medicine</i> , 2017, 14, e1002299.	8.4	64
80	A systematic review of sub-microscopic <i>Plasmodium vivax</i> infection. <i>Malaria Journal</i> , 2015, 14, 360.	2.3	63
81	Contrasting Transmission Dynamics of Co-endemic <i>Plasmodium vivax</i> and <i>P. falciparum</i> : Implications for Malaria Control and Elimination. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003739.	3.0	63
82	Diagnosis and Treatment of <i>Plasmodium vivax</i> Malaria. <i>Advances in Parasitology</i> , 2012, 80, 203-270.	3.2	62
83	Malaria Elimination: Time to Target All Species. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 99, 17-23.	1.4	62
84	Assessment of therapeutic responses to gametocytocidal drugs in <i>Plasmodium falciparum</i> malaria. <i>Malaria Journal</i> , 2014, 13, 483.	2.3	61
85	Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated <i>falciparum</i> malaria: a literature review and meta-analysis of individual patient data. <i>BMC Medicine</i> , 2015, 13, 212.	5.5	61
86	Greater Endothelial Activation, Weibel-Palade Body Release and Host Inflammatory Response to <i>Plasmodium vivax</i> , Compared with <i>Plasmodium falciparum</i> : A Prospective Study in Papua, Indonesia. <i>Journal of Infectious Diseases</i> , 2010, 202, 109-112.	4.0	60
87	Evaluation of splenic accumulation and colocalization of immature reticulocytes and <i>Plasmodium vivax</i> in asymptomatic malaria: A prospective human splenectomy study. <i>PLoS Medicine</i> , 2021, 18, e1003632.	8.4	60
88	Genomic analysis of a pre-elimination Malaysian <i>Plasmodium vivax</i> population reveals selective pressures and changing transmission dynamics. <i>Nature Communications</i> , 2018, 9, 2585.	12.8	59
89	Artesunate-mefloquine versus chloroquine for treatment of uncomplicated <i>Plasmodium knowlesi</i> malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 180-188.	9.1	58
90	The Darwin Prospective Melioidosis Study: a 30-year prospective, observational investigation. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1737-1746.	9.1	58

#	ARTICLE	IF	CITATIONS
91	World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs. <i>Malaria Journal</i> , 2007, 6, 119.	2.3	57
92	Risk of <i>Plasmodium vivax</i> parasitaemia after <i>Plasmodium falciparum</i> infection: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 91-101.	9.1	56
93	<i>Plasmodium vivax</i> trophozoites insensitive to chloroquine. <i>Malaria Journal</i> , 2008, 7, 94.	2.3	55
94	Severe Malarial Thrombocytopenia: A Risk Factor for Mortality in Papua, Indonesia. <i>Journal of Infectious Diseases</i> , 2015, 211, 623-634.	4.0	55
95	<i>Ex Vivo</i> Activity of Histone Deacetylase Inhibitors against Multidrug-Resistant Clinical Isolates of <i>Plasmodium falciparum</i> and <i>P. vivax</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 961-966.	3.2	53
96	Challenges for achieving safe and effective radical cure of <i>Plasmodium vivax</i> : a round table discussion of the APMEN Vivax Working Group. <i>Malaria Journal</i> , 2017, 16, 141.	2.3	52
97	The challenges of introducing routine G6PD testing into radical cure: a workshop report. <i>Malaria Journal</i> , 2015, 14, 377.	2.3	51
98	A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance. <i>Nature Communications</i> , 2017, 8, 15159.	12.8	51
99	An open dataset of <i>Plasmodium falciparum</i> genome variation in 7,000 worldwide samples. <i>Wellcome Open Research</i> , 2021, 6, 42.	1.8	51
100	Field evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity. <i>PLoS ONE</i> , 2018, 13, e0206331.	2.5	50
101	Genomic Analysis of <i>Plasmodium vivax</i> in Southern Ethiopia Reveals Selective Pressures in Multiple Parasite Mechanisms. <i>Journal of Infectious Diseases</i> , 2019, 220, 1738-1749.	4.0	50
102	Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. <i>PLoS Medicine</i> , 2017, 14, e1002212.	8.4	50
103	Submicroscopic and Asymptomatic <i>Plasmodium</i> Parasitaemia Associated with Significant Risk of Anaemia in Papua, Indonesia. <i>PLoS ONE</i> , 2016, 11, e0165340.	2.5	48
104	High burden of diabetic foot infections in the top end of Australia: An emerging health crisis (DEFINE) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.8	47
105	Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis. <i>Malaria Journal</i> , 2015, 14, 359.	2.3	47
106	Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. <i>PLoS Medicine</i> , 2018, 15, e1002579.	8.4	47
107	The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study. <i>BMC Medicine</i> , 2020, 18, 28.	5.5	47
108	Circulating Neutrophil Extracellular Traps and Neutrophil Activation Are Increased in Proportion to Disease Severity in Human Malaria. <i>Journal of Infectious Diseases</i> , 2019, 219, 1994-2004.	4.0	46

#	ARTICLE	IF	CITATIONS
109	Plasmodium vivax Population Structure and Transmission Dynamics in Sabah Malaysia. PLoS ONE, 2013, 8, e82553.	2.5	45
110	Plasmodium vivax treatments. Current Opinion in Infectious Diseases, 2011, 24, 578-585.	3.1	44
111	Efficacy of Artesunate-mefloquine for Chloroquine-resistant Plasmodium vivax Malaria in Malaysia: An Open-label, Randomized, Controlled Trial. Clinical Infectious Diseases, 2016, 62, 1403-1411.	5.8	44
112	Coma Associated with Microscopy-Diagnosed Plasmodium vivax: A Prospective Study in Papua, Indonesia. PLoS Neglected Tropical Diseases, 2011, 5, e1032.	3.0	44
113	Gametocyte Dynamics and the Role of Drugs in Reducing the Transmission Potential of Plasmodium vivax. Journal of Infectious Diseases, 2013, 208, 801-812.	4.0	43
114	Methods for the field evaluation of quantitative G6PD diagnostics: a review. Malaria Journal, 2017, 16, 361.	2.3	43
115	Investigating the Efficacy of Triple Artemisinin-Based Combination Therapies for Treating Plasmodium falciparum Malaria Patients Using Mathematical Modeling. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	43
116	Intrahost Selection of Plasmodium falciparum pfmdr1 Alleles after Antimalarial Treatment on the Northwestern Border of Thailand. Journal of Infectious Diseases, 2007, 195, 134-141.	4.0	42
117	Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Malaria Journal, 2012, 11, 303.	2.3	42
118	Impaired Skeletal Muscle Microvascular Function and Increased Skeletal Muscle Oxygen Consumption in Severe Falciparum Malaria. Journal of Infectious Diseases, 2013, 207, 528-536.	4.0	42
119	A Randomized Pilot Study of L-Arginine Infusion in Severe Falciparum Malaria: Preliminary Safety, Efficacy and Pharmacokinetics. PLoS ONE, 2013, 8, e69587.	2.5	42
120	Inferred relatedness and heritability in malaria parasites. Proceedings of the Royal Society B: Biological Sciences, 2010, 277, 2531-2540.	2.6	41
121	Electrocardiographic Safety Evaluation of Dihydroartemisinin+Piperaquine in the Treatment of Uncomplicated falciparum Malaria. American Journal of Tropical Medicine and Hygiene, 2007, 77, 447-450.	1.4	41
122	UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	40
123	Comparative <i>Ex Vivo</i> Activity of Novel Endoperoxides in Multidrug-Resistant Plasmodium falciparum and P. vivax. Antimicrobial Agents and Chemotherapy, 2012, 56, 5258-5263.	3.2	38
124	Decreased Endothelial Nitric Oxide Bioavailability, Impaired Microvascular Function, and Increased Tissue Oxygen Consumption in Children with Falciparum Malaria. Journal of Infectious Diseases, 2014, 210, 1627-1632.	4.0	38
125	Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: A longitudinal surveillance study. PLoS Medicine, 2019, 16, e1002815.	8.4	38
126	<i>Ex Vivo</i> Drug Susceptibility of Ferroquine against Chloroquine-Resistant Isolates of Plasmodium falciparum and P. vivax. Antimicrobial Agents and Chemotherapy, 2011, 55, 4461-4464.	3.2	37



#	ARTICLE	IF	CITATIONS
127	The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. <i>BMC Medicine</i> , 2015, 13, 66.	5.5	37
128	Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis. <i>PLoS Medicine</i> , 2019, 16, e1002992.	8.4	37
129	Dihydroartemisinin-Piperaquine Treatment of Multidrug Resistant Falciparum and Vivax Malaria in Pregnancy. <i>PLoS ONE</i> , 2014, 9, e84976.	2.5	37
130	<i>In Vitro</i> Activity of Pyronaridine against Multidrug-Resistant <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5146-5150.	3.2	36
131	Highly Effective Therapy for Maternal Malaria Associated With a Lower Risk of Vertical Transmission. <i>Journal of Infectious Diseases</i> , 2011, 204, 1613-1619.	4.0	36
132	The clinical implications of thrombocytopenia in adults with severe falciparum malaria: a retrospective analysis. <i>BMC Medicine</i> , 2015, 13, 97.	5.5	36
133	Genomic Characterization of Recrudescence <i>Plasmodium malariae</i> after Treatment with Artemether/Lumefantrine. <i>Emerging Infectious Diseases</i> , 2017, 23, 1300-1307.	4.3	36
134	Treatment-seeking behaviour and associated costs for malaria in Papua, Indonesia. <i>Malaria Journal</i> , 2016, 15, 536.	2.3	35
135	Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Response Efficacy Modeling. <i>PLoS Medicine</i> , 2016, 13, e1002138.	8.4	35
136	Stronger Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors against Clinical Isolates of <i>Plasmodium vivax</i> than against Those of <i>P. falciparum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2435-2441.	3.2	34
137	Considerations on the use of nucleic acid-based amplification for malaria parasite detection. <i>Malaria Journal</i> , 2011, 10, 323.	2.3	34
138	The haematological consequences of <i>Plasmodium vivax</i> malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. <i>BMC Medicine</i> , 2019, 17, 151.	5.5	34
139	A Comparison of Three Quantitative Methods to Estimate G6PD Activity in the Chittagong Hill Tracts, Bangladesh. <i>PLoS ONE</i> , 2017, 12, e0169930.	2.5	34
140	Pharmacokinetics of L-Arginine in Adults with Moderately Severe Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4381-4387.	3.2	33
141	Early parasitological response following artemisinin-containing regimens: a critical review of the literature. <i>Malaria Journal</i> , 2013, 12, 125.	2.3	33
142	Impaired Systemic Tetrahydrobiopterin Bioavailability and Increased Dihydrobiopterin in Adult Falciparum Malaria: Association with Disease Severity, Impaired Microvascular Function and Increased Endothelial Activation. <i>PLoS Pathogens</i> , 2015, 11, e1004667.	4.7	33
143	Variation in Complexity of Infection and Transmission Stability between Neighbouring Populations of <i>Plasmodium vivax</i> in Southern Ethiopia. <i>PLoS ONE</i> , 2015, 10, e0140780.	2.5	33
144	Nocardiosis in the Tropical Northern Territory of Australia, 1997-2014. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw208.	0.9	32

#	ARTICLE	IF	CITATIONS
145	The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network. PLoS Medicine, 2020, 17, e1003393.	8.4	32
146	Electrocardiographic safety evaluation of dihydroartemisinin piperazine in the treatment of uncomplicated falciparum malaria. American Journal of Tropical Medicine and Hygiene, 2007, 77, 447-50.	1.4	32
147	Glycocalyx Breakdown Is Associated With Severe Disease and Fatal Outcome in Plasmodium falciparum Malaria. Clinical Infectious Diseases, 2019, 69, 1712-1720.	5.8	31
148	Implementing parasite genotyping into national surveillance frameworks: feedback from control programmes and researchers in the Asia-Pacific region. Malaria Journal, 2020, 19, 271.	2.3	31
149	Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis. PLoS Medicine, 2020, 17, e1003084.	8.4	31
150	Severe Congenital Malaria Acquired in utero. American Journal of Tropical Medicine and Hygiene, 2010, 82, 563-565.	1.4	30
151	Impaired Pulmonary Nitric Oxide Bioavailability in Pulmonary Tuberculosis: Association With Disease Severity and Delayed Mycobacterial Clearance With Treatment. Journal of Infectious Diseases, 2013, 208, 616-626.	4.0	29
152	Genomic Analysis Reveals a Common Breakpoint in Amplifications of the Plasmodium vivax Multidrug Resistance 1 Locus in Thailand. Journal of Infectious Diseases, 2016, 214, 1235-1242.	4.0	29
153	Improving Case Definitions for Severe Malaria. PLoS Medicine, 2007, 4, e267.	8.4	28
154	Chemotherapeutic Strategies for Reducing Transmission of Plasmodium vivax Malaria. Advances in Parasitology, 2012, 80, 271-300.	3.2	28
155	The changing epidemiology of Plasmodium vivax: Insights from conventional and novel surveillance tools. PLoS Medicine, 2021, 18, e1003560.	8.4	28
156	Safety Profile of L-Arginine Infusion in Moderately Severe Falciparum Malaria. PLoS ONE, 2008, 3, e2347.	2.5	28
157	G6PD Deficiency and Antimalarial Efficacy for Uncomplicated Malaria in Bangladesh: A Prospective Observational Study. PLoS ONE, 2016, 11, e0154015.	2.5	28
158	Preserved Dendritic Cell HLA-DR Expression and Reduced Regulatory T Cell Activation in Asymptomatic Plasmodium falciparum and P. vivax Infection. Infection and Immunity, 2015, 83, 3224-3232.	2.2	27
159	The efficacy of dihydroartemisinin-piperazine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis. PLoS Medicine, 2019, 16, e1002928.	8.4	27
160	In Vivo and In Vitro Efficacy of Chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia. Antimicrobial Agents and Chemotherapy, 2011, 55, 197-202.	3.2	26
161	Effective Preparation of Plasmodium vivax Field Isolates for High-Throughput Whole Genome Sequencing. PLoS ONE, 2013, 8, e53160.	2.5	26
162	Making the Most of Clinical Data: Reviewing the Role of Pharmacokinetic-Pharmacodynamic Models of Anti-malarial Drugs. AAPS Journal, 2014, 16, 962-974.	4.4	26

#	ARTICLE	IF	CITATIONS
163	Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia. <i>Malaria Journal</i> , 2015, 14, 525.	2.3	26
164	Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients. <i>PLoS ONE</i> , 2017, 12, e0168780.	2.5	26
165	Artemether-Lumefantrine Versus Chloroquine for the Treatment of Uncomplicated Plasmodium knowlesi Malaria: An Open-Label Randomized Controlled Trial CAN KNOW. <i>Clinical Infectious Diseases</i> , 2018, 66, 229-236.	5.8	26
166	Implications of population-level immunity for the emergence of artemisinin-resistant malaria: a mathematical model. <i>Malaria Journal</i> , 2018, 17, 279.	2.3	26
167	Baseline results of a living systematic review for COVID-19 clinical trial registrations. <i>Wellcome Open Research</i> , 2020, 5, 116.	1.8	26
168	Expression of Plasmodium vivax <i>crt</i> Is Related to Parasite Stage but Not <i>Ex Vivo</i> Chloroquine Susceptibility. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 361-367.	3.2	25
169	Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6 <i>PD</i> deficiency. <i>Medical Journal of Australia</i> , 2020, 212, 152.	1.7	25
170	The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to <i>Plasmodium falciparum</i> parasite resistance. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	25
171	Chloroquine efficacy for Plasmodium vivax in Myanmar in populations with high genetic diversity and moderate parasite gene flow. <i>Malaria Journal</i> , 2017, 16, 281.	2.3	24
172	An Analytical Method for Assessing Stage-Specific Drug Activity in Plasmodium vivax Malaria: Implications for <i>Ex Vivo</i> Drug Susceptibility Testing. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1772.	3.0	23
173	Differences in PfEMP1s recognized by antibodies from patients with uncomplicated or severe malaria. <i>Malaria Journal</i> , 2016, 15, 258.	2.3	23
174	Plasmodium vivax infection: a major determinant of severe anaemia in infancy. <i>Malaria Journal</i> , 2016, 15, 321.	2.3	23
175	Therapeutic Response to Dihydroartemisinin+Piperaquine for P. falciparum and P. vivax Nine Years after Its Introduction in Southern Papua, Indonesia. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 677-682.	1.4	23
176	Artemisinin Combination Therapy for Malaria: Beyond Good Efficacy. <i>Clinical Infectious Diseases</i> , 2009, 49, 1638-1640.	5.8	22
177	In Vivo and In Vitro Efficacy of Amodiaquine Monotherapy for Treatment of Infection by Chloroquine-Resistant <i>Plasmodium vivax</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1094-1099.	3.2	22
178	The burden and treatment of HIV in tuberculosis patients in Papua Province, Indonesia: a prospective observational study. <i>BMC Infectious Diseases</i> , 2010, 10, 362.	2.9	22
179	Genetic diversity and population structure of Plasmodium vivax in Central China. <i>Malaria Journal</i> , 2014, 13, 262.	2.3	22
180	Targeting vivax malaria in the Asia Pacific: The Asia Pacific Malaria Elimination Network Vivax Working Group. <i>Malaria Journal</i> , 2015, 14, 484.	2.3	22

#	ARTICLE	IF	CITATIONS
181	Efficacy of Single-Dose Primaquine With Artemisinin Combination Therapy on Plasmodium falciparum Gametocytes and Transmission: An Individual Patient Meta-Analysis. <i>Journal of Infectious Diseases</i> , 2022, 225, 1215-1226.	4.0	22
182	Where chloroquine still works: the genetic make-up and susceptibility of Plasmodium vivax to chloroquine plus primaquine in Bhutan. <i>Malaria Journal</i> , 2016, 15, 277.	2.3	21
183	Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 367-376.	9.1	21
184	Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2012, 2, 126-133.	3.4	20
185	Potent Ex Vivo Activity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparum and Plasmodium vivax. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6117-6124.	3.2	20
186	Loss of complement regulatory proteins on uninfected erythrocytes in vivax and falciparum malaria anemia. <i>JCI Insight</i> , 2018, 3, .	5.0	20
187	Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data. <i>PLoS Medicine</i> , 2020, 17, e1003040.	8.4	20
188	Barriers to routine G6PD testing prior to treatment with primaquine. <i>Malaria Journal</i> , 2017, 16, 329.	2.3	19
189	Single-dose radical cure of Plasmodium vivax : a step closer. <i>Lancet</i> , The, 2014, 383, 1020-1021.	13.7	18
190	Early and late mortality after malaria in young children in Papua, Indonesia. <i>BMC Infectious Diseases</i> , 2019, 19, 922.	2.9	18
191	Rapid Clinical Assessment to Facilitate the Triage of Adults with Falciparum Malaria, a Retrospective Analysis. <i>PLoS ONE</i> , 2014, 9, e87020.	2.5	18
192	Plasmodium falciparum Activates CD16+ Dendritic Cells to Produce Tumor Necrosis Factor and Interleukin-10 in Subpatent Malaria. <i>Journal of Infectious Diseases</i> , 2019, 219, 660-671.	4.0	17
193	Molecular Epidemiology of P. vivax in Iran: High Diversity and Complex Sub-Structure Using Neutral Markers, but No Evidence of Y976F Mutation at pvmdr1. <i>PLoS ONE</i> , 2016, 11, e0166124.	2.5	17
194	Treatment-Seeking Behavior after the Implementation of a Unified Policy of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Papua, Indonesia. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 543-550.	1.4	17
195	3,3-Di-substituted 5,5-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2485-2498.	6.4	16
196	Asymptomatic Vivax and Falciparum Parasitaemia with Helminth Co-Infection: Major Risk Factors for Anaemia in Early Life. <i>PLoS ONE</i> , 2016, 11, e0160917.	2.5	16
197	Genetic micro-epidemiology of malaria in Papua Indonesia: Extensive P. vivax diversity and a distinct subpopulation of asymptomatic P. falciparum infections. <i>PLoS ONE</i> , 2017, 12, e0177445.	2.5	16
198	Passively versus Actively Detected Malaria: Similar Genetic Diversity but Different Complexity of Infection. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 1788-1796.	1.4	16

#	ARTICLE	IF	CITATIONS
199	An open dataset of Plasmodium vivax genome variation in 1,895 worldwide samples. Wellcome Open Research, 0, 7, 136.	1.8	16
200	Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis. PLoS Neglected Tropical Diseases, 2017, 11, e0005602.	3.0	15
201	Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study. PLoS Medicine, 2021, 18, e1003614.	8.4	15
202	Field evaluation of the diagnostic performance of EasyScan GO: a digital malaria microscopy device based on machine-learning. Malaria Journal, 2022, 21, 122.	2.3	15
203	Towards optimal design of anti-malarial pharmacokinetic studies. Malaria Journal, 2009, 8, 189.	2.3	14
204	Quantification of Plasmodium ex vivo drug susceptibility by flow cytometry. Malaria Journal, 2015, 14, 417.	2.3	14
205	Statistical methods to derive efficacy estimates of anti-malarials for uncomplicated Plasmodium falciparum malaria: pitfalls and challenges. Malaria Journal, 2017, 16, 430.	2.3	14
206	Spectrophotometry assays to determine G6PD activity from Trinity Biotech and Pointe Scientific G6PD show good correlation. BMC Research Notes, 2018, 11, 855.	1.4	14
207	Repeatability and reproducibility of a handheld quantitative G6PD diagnostic. PLoS Neglected Tropical Diseases, 2022, 16, e0010174.	3.0	14
208	Antimalarial Therapies in Children from Papua New Guinea. New England Journal of Medicine, 2009, 360, 1254-1255.	27.0	13
209	Age-Related Susceptibility to Severe Malaria Associated with Galectin-2 in Highland Papuans. Journal of Infectious Diseases, 2010, 202, 117-124.	4.0	13
210	A study of the TNF/LTA/LTB locus and susceptibility to severe malaria in highland papuan children and adults. Malaria Journal, 2010, 9, 302.	2.3	13
211	Treatment policy change to dihydroartemisinin-piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes. Malaria Journal, 2015, 14, 272.	2.3	13
212	Optimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant Plasmodium falciparum distributions in Southeast Asia. International Journal of Health Geographics, 2016, 15, 37.	2.5	13
213	Towards harmonization of microscopy methods for malaria clinical research studies. Malaria Journal, 2020, 19, 324.	2.3	13
214	Transcriptional profiling and immunophenotyping show sustained activation of blood monocytes in subpatent Plasmodium falciparum infection. Clinical and Translational Immunology, 2020, 9, e1144.	3.8	13
215	VivaxGEN: An open access platform for comparative analysis of short tandem repeat genotyping data in Plasmodium vivax populations. PLoS Neglected Tropical Diseases, 2017, 11, e0005465.	3.0	13
216	Further Evidence of Increasing Diversity of Plasmodium vivax in the Republic of Korea in Recent Years. PLoS ONE, 2016, 11, e0151514.	2.5	13

#	ARTICLE	IF	CITATIONS
217	Defining the relationship between Plasmodium vivax parasite rate and clinical disease. Malaria Journal, 2015, 14, 191.	2.3	12
218	Contrasting <i>Ex Vivo</i> Efficacies of Reversed Chloroquine Compounds in Chloroquine-Resistant Plasmodium falciparum and P. vivax Isolates. Antimicrobial Agents and Chemotherapy, 2015, 59, 5721-5726.	3.2	12
219	Characterization of blood dendritic and regulatory T cells in asymptomatic adults with sub-microscopic Plasmodium falciparum or Plasmodium vivax infection. Malaria Journal, 2016, 15, 328.	2.3	12
220	Analysis of ex vivo drug response data of Plasmodium clinical isolates: the pros and cons of different computer programs and online platforms. Malaria Journal, 2016, 15, 137.	2.3	12
221	Molecular analysis demonstrates high prevalence of chloroquine resistance but no evidence of artemisinin resistance in Plasmodium falciparum in the Chittagong Hill Tracts of Bangladesh. Malaria Journal, 2017, 16, 335.	2.3	12
222	Implementing radical cure diagnostics for malaria: user perspectives on G6PD testing in Bangladesh. Malaria Journal, 2021, 20, 217.	2.3	12
223	Increased Carboxyhemoglobin in Adult Falciparum Malaria is Associated With Disease Severity and Mortality. Journal of Infectious Diseases, 2013, 208, 813-817.	4.0	11
224	High Risk of Plasmodium vivax Malaria Following Splenectomy in Papua, Indonesia. Clinical Infectious Diseases, 2019, 68, 51-60.	5.8	11
225	Cost-Effectiveness Analysis of Sex-Stratified Plasmodium vivax Treatment Strategies Using Available G6PD Diagnostics to Accelerate Access to Radical Cure. American Journal of Tropical Medicine and Hygiene, 2020, 103, 394-403.	1.4	11
226	Human T cell recognition of the blood stage antigen Plasmodium hypoxanthine guanine xanthine phosphoribosyl transferase (HGXPRT) in acute malaria. Malaria Journal, 2009, 8, 122.	2.3	10
227	Potential of Artemisinin-Based Combination Therapies to Block Malaria Transmission. Journal of Infectious Diseases, 2013, 207, 1627-1629.	4.0	10
228	A study protocol for a randomised open-label clinical trial of artesunate-mefloquine versus chloroquine in patients with non-severe Plasmodium knowlesi malaria in Sabah, Malaysia (ACT KNOW) Tj ETQq0 0 0.0gBT /Overlock 10 T		
229	Piperaquine Pharmacokinetics during Intermittent Preventive Treatment for Malaria in Pregnancy. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	10
230	Glucose-6-phosphate dehydrogenase activity in individuals with and without malaria: Analysis of clinical trial, cross-sectional and case-control data from Bangladesh. PLoS Medicine, 2021, 18, e1003576.	8.4	10
231	The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia. PLoS Neglected Tropical Diseases, 2020, 14, e0008838.	3.0	10
232	The WorldWide Antimalarial Resistance Network Clinical Trials Publication Library: A Live, Open-Access Database of Plasmodium Treatment Efficacy Trials. American Journal of Tropical Medicine and Hygiene, 2020, 103, 359-368.	1.4	10
233	Improving the availability of artesunate for treatment of severe malaria. Medical Journal of Australia, 2006, 184, 3-4.	1.7	9
234	A robust design for identification of the Parasite Clearance Estimator. Malaria Journal, 2013, 12, 410.	2.3	9

#	ARTICLE	IF	CITATIONS
235	Molecular surveillance over 14 years confirms reduction of <i>Plasmodium vivax</i> and <i>falciparum</i> transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008295.	3.0	9
236	Haematological consequences of acute uncomplicated <i>falciparum</i> malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data. <i>BMC Medicine</i> , 2022, 20, 85.	5.5	9
237	Molecular profiling reveals features of clinical immunity and immunosuppression in asymptomatic <i>P. falciparum</i> malaria. <i>Molecular Systems Biology</i> , 2022, 18, e10824.	7.2	9
238	The effect of varying analytical methods on estimates of anti-malarial clinical efficacy. <i>Malaria Journal</i> , 2009, 8, 77.	2.3	8
239	The ethics of using placebo in randomised controlled trials: a case study of a <i>Plasmodium vivax</i> antirelapse trial. <i>BMC Medical Ethics</i> , 2018, 19, 19.	2.4	8
240	<i>Plasmodium falciparum</i> artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance. <i>Malaria Journal</i> , 2018, 17, 463.	2.3	8
241	Analysis of erroneous data entries in paper based and electronic data collection. <i>BMC Research Notes</i> , 2019, 12, 537.	1.4	8
242	Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts, Bangladesh. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008697.	3.0	8
243	Variation in Glucose-6-Phosphate Dehydrogenase activity following acute malaria. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010406.	3.0	8
244	Trends in malaria research in 11 Asian Pacific countries: an analysis of peer-reviewed publications over two decades. <i>Malaria Journal</i> , 2011, 10, 131.	2.3	7
245	Differential Cellular Recognition of Antigens During Acute <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> Malaria. <i>Journal of Infectious Diseases</i> , 2011, 203, 1192-1199.	4.0	7
246	<i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> Demonstrate Contrasting Chloroquine Resistance Reversal Phenotypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	7
247	Safety of primaquine in infants with <i>Plasmodium vivax</i> malaria in Papua, Indonesia. <i>Malaria Journal</i> , 2019, 18, 111.	2.3	7
248	Multi-locus genotyping reveals established endemicity of a geographically distinct <i>Plasmodium vivax</i> population in Mauritania, West Africa. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008945.	3.0	7
249	Provider and household costs of <i>Plasmodium vivax</i> malaria episodes: a multicountry comparative analysis of primary trial data. <i>Bulletin of the World Health Organization</i> , 2019, 97, 828-836.	3.3	7
250	Opening the policy blackbox: unravelling the process for changing national diagnostic and treatment guidelines for <i>vivax</i> malaria in seven countries. <i>Malaria Journal</i> , 2021, 20, 428.	2.3	7
251	Neurosyphilis: Still prevalent and overlooked in an at risk population. <i>PLoS ONE</i> , 2020, 15, e0238617.	2.5	7
252	Expanding the Use of Primaquine for the Radical Cure of <i>Plasmodium vivax</i> . <i>Clinical Infectious Diseases</i> , 2018, 67, 1008-1009.	5.8	6

#	ARTICLE	IF	CITATIONS
253	High-dimensional mass cytometry identifies T cell and B cell signatures predicting reduced risk of <i>Plasmodium vivax</i> malaria. <i>JCI Insight</i> , 2021, 6, .	5.0	6
254	Adults with <i>Plasmodium falciparum</i> malaria have higher magnitude and quality of circulating T-follicular helper cells compared to children. <i>EBioMedicine</i> , 2022, 75, 103784.	6.1	6
255	Improving the Radical Cure of <i>Plasmodium vivax</i> Malaria. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 3-4.	1.4	5
256	Low risk of recurrence following artesunateâ€“Sulphadoxineâ€“pyrimethamine plus primaquine for uncomplicated <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> infections in the Republic of the Sudan. <i>Malaria Journal</i> , 2018, 17, 117.	2.3	5
257	Evaluating antimalarial efficacy in single-armed and comparative drug trials using competing risk survival analysis: a simulation study. <i>BMC Medical Research Methodology</i> , 2019, 19, 107.	3.1	5
258	Precarity at the Margins of Malaria Control in the Chittagong Hill Tracts in Bangladesh: A Mixed-Methods Study. <i>Pathogens</i> , 2020, 9, 840.	2.8	5
259	Genetic diversity and neutral selection in <i>Plasmodium vivax</i> erythrocyte binding protein correlates with patient antigenicity. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008202.	3.0	5
260	Nonlinear Mixed-Effects Modelling of In Vitro Drug Susceptibility and Molecular Correlates of Multidrug Resistant <i>Plasmodium falciparum</i> . <i>PLoS ONE</i> , 2013, 8, e69505.	2.5	5
261	Maximising the public health benefit of antimalarials. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 654-655.	9.1	4
262	Detection of <i>Mycobacterium leprae</i> by PCR Testing of Sputa from a Patient with Pulmonary <i>Cryptococcus</i> Coinfection in Northern Australia. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3811-3812.	3.9	4
263	Performance and user acceptance of the Bhutan febrile and malaria information system: report from a pilot study. <i>Malaria Journal</i> , 2016, 15, 52.	2.3	4
264	Spaceâ€“Time Clustering Characteristics of Malaria in Bhutan at the End Stages of Elimination. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5553.	2.6	4
265	Longitudinal ex vivo and molecular trends of chloroquine and piperazine activity against <i>Plasmodium falciparum</i> and <i>P. vivax</i> before and after introduction of artemisinin-based combination therapy in Papua, Indonesia. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2021, 17, 46-56.	3.4	4
266	Diagnostic Practices and Treatment for <i>P. vivax</i> in the InterEthnic Therapeutic Encounter of South-Central Vietnam: A Mixed-Methods Study. <i>Pathogens</i> , 2021, 10, 26.	2.8	4
267	Drugs that reduce transmission of falciparum malaria. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 585-586.	9.1	3
268	Dealing with indeterminate outcomes in antimalarial drug efficacy trials: a comparison between complete case analysis, multiple imputation and inverse probability weighting. <i>BMC Medical Research Methodology</i> , 2019, 19, 215.	3.1	3
269	A population of CD4 hi CD38 hi T cells correlates with disease severity in patients with acute malaria. <i>Clinical and Translational Immunology</i> , 2020, 9, e1209.	3.8	3
270	Malaria-related hospitalization during childhood in Papua, Indonesia: A retrospective cohort study. <i>PLoS ONE</i> , 2020, 15, e0228018.	2.5	3



#	ARTICLE	IF	CITATIONS
271	Identifying Targets of Protective Antibodies against Severe Malaria in Papua, Indonesia, Using Locally Expressed Domains of Plasmodium falciparum Erythrocyte Membrane Protein 1. <i>Infection and Immunity</i> , 2022, 90, IAI0043521.	2.2	3
272	Malaria eradication revisited. <i>International Journal of Epidemiology</i> , 2022, 51, 382-392.	1.9	3
273	Global extent of chloroquine-resistant Plasmodium vivax – Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 630-631.	9.1	2
274	Disseminating clinical study results to trial participants in Ethiopia: insights and lessons learned. <i>Malaria Journal</i> , 2020, 19, 205.	2.3	2
275	Tafenoquine for children: a step towards implementation. <i>The Lancet Child and Adolescent Health</i> , 2022, 6, 72-73.	5.6	2
276	A fluorometric assay to determine the protective effect of glucose-6-phosphate dehydrogenase (G6PD) against a Plasmodium spp. infection in females heterozygous for the G6PD gene: proof of concept in Plasmodium falciparum. <i>BMC Research Notes</i> , 2022, 15, 76.	1.4	2
277	Cooperation in Countering Artemisinin Resistance in Africa: Learning from COVID-19. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, , .	1.4	2
278	Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA). <i>Trials</i> , 2022, 23, 416.	1.6	2
279	Geographical distribution and genetic diversity of Plasmodium vivax reticulocyte binding protein 1a correlates with patient antigenicity. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010492.	3.0	2
280	Heterogeneity in prevalence of subclinical Plasmodium falciparum and Plasmodium vivax infections but no parasite genomic clustering in the Chittagong Hill Tracts, Bangladesh. <i>Malaria Journal</i> , 2022, 21, .	2.3	2
281	Preface. <i>Advances in Parasitology</i> , 2013, 81, xi-xii.	3.2	1
282	Development and Validation of an <i>In Silico</i> Decision Tool To Guide Optimization of Intravenous Artesunate Dosing Regimens for Severe Falciparum Malaria Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	1
283	Bold measures to accelerate malaria elimination. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1480-1481.	9.1	1
284	Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis. <i>Malaria Journal</i> , 2022, 21, 106.	2.3	1
285	Preface. <i>Advances in Parasitology</i> , 2012, 80, ix-x.	3.2	0
286	Primaquine for Plasmodium vivax malaria treatment – Authors' reply. <i>Lancet</i> , The, 2020, 395, 1972.	18.7	0
287	Delayed Diagnosis of Whipple's Disease Complicated by Jarisch-Herxheimer Reaction to Ceftriaxone Treatment: A Case Report and Literature Review. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 40.	2.3	0
288	Title is missing!. , 2020, 17, e1003084.		0

#	ARTICLE	IF	CITATIONS
289	Title is missing!. , 2020, 17, e1003084.		0
290	Title is missing!. , 2020, 17, e1003084.		0
291	Title is missing!. , 2020, 17, e1003084.		0
292	Title is missing!. , 2020, 17, e1003084.		0
293	Title is missing!. , 2020, 17, e1003393.		0
294	Title is missing!. , 2020, 17, e1003393.		0
295	Title is missing!. , 2020, 17, e1003393.		0
296	Title is missing!. , 2020, 17, e1003393.		0
297	Title is missing!. , 2020, 17, e1003393.		0
298	Title is missing!. , 2019, 16, e1002992.		0
299	Title is missing!. , 2019, 16, e1002992.		0
300	Title is missing!. , 2019, 16, e1002992.		0
301	Title is missing!. , 2019, 16, e1002992.		0
302	Title is missing!. , 2020, 14, e0008295.		0
303	Title is missing!. , 2020, 14, e0008295.		0
304	Title is missing!. , 2020, 14, e0008295.		0
305	Title is missing!. , 2020, 14, e0008295.		0
306	Title is missing!. , 2020, 14, e0008295.		0

#	ARTICLE	IF	CITATIONS
307	Title is missing!. , 2020, 14, e0008945.		0
308	Title is missing!. , 2020, 14, e0008945.		0
309	Title is missing!. , 2020, 14, e0008945.		0
310	Title is missing!. , 2020, 14, e0008945.		0
311	Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts, Bangladesh. , 2020, 14, e0008697.		0
312	Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts, Bangladesh. , 2020, 14, e0008697.		0
313	Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts, Bangladesh. , 2020, 14, e0008697.		0
314	Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts, Bangladesh. , 2020, 14, e0008697.		0
315	Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts, Bangladesh. , 2020, 14, e0008697.		0
316	Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts, Bangladesh. , 2020, 14, e0008697.		0
317	Title is missing!. , 2020, 14, e0008202.		0
318	Title is missing!. , 2020, 14, e0008202.		0
319	Title is missing!. , 2020, 14, e0008202.		0
320	Title is missing!. , 2020, 14, e0008202.		0
321	Neurosyphilis: Still prevalent and overlooked in an at risk population. , 2020, 15, e0238617.		0
322	Neurosyphilis: Still prevalent and overlooked in an at risk population. , 2020, 15, e0238617.		0
323	Neurosyphilis: Still prevalent and overlooked in an at risk population. , 2020, 15, e0238617.		0
324	Neurosyphilis: Still prevalent and overlooked in an at risk population. , 2020, 15, e0238617.		0

#	ARTICLE	IF	CITATIONS
325	Title is missing!. , 2020, 16, e1009133.		0
326	Title is missing!. , 2020, 16, e1009133.		0
327	Title is missing!. , 2020, 16, e1009133.		0
328	Title is missing!. , 2020, 16, e1009133.		0
329	Intermittent screening and treatment for malaria complementary to routine immunisation in the first year of life in Papua, Indonesia: a cluster randomised superiority trial. BMC Medicine, 2022, 20, .	5.5	0